WMT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Not a good buy right now for an impatient investor. WMT’s medium-term trend is still bullish (strong moving-average structure and solid fundamentals), but the near-term setup is less attractive: price is sitting just below key resistance (~120.75), MACD remains below zero (momentum not fully confirmed), implied volatility is elevated ahead of the 2026-02-19 pre-market earnings/guidance event, and both insider activity and recent Congress activity skew to selling. If you must act immediately, this is more of a HOLD than a fresh BUY at ~119.
Trend/structure: Bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) supports an uptrend. Momentum: MACD histogram -0.217 (below 0) but negatively contracting—bearish momentum is fading, yet not a clean bullish reversal signal. RSI: RSI_6 at 66.18 (neutral-to-slightly warm), not overbought but close enough to suggest limited immediate upside without a catalyst. Levels: Pivot 118.40 (price 118.99 is slightly above, supportive). Resistance at R1 120.75 then R2 122.20; support at S1 116.06 then S2 114.61. With price under R1, near-term reward/risk is less favorable for an impatient entry.
Intellectia Proprietary Trading Signals: Intellectia Proprietary Trading Signals
Upcoming earnings (2026-02-19 pre-market): strong recent execution could reinforce the bull case if guidance holds.
Fundamental momentum: 2026/Q3 showed solid operating leverage (Net Income +34.21% YoY; EPS +35.09% YoY) on healthy revenue growth (+5.84% YoY).
Strategic tailwinds highlighted by analysts: AI/automation, improving e-commerce profitability, continued share gains across income cohorts.
News tone: pharmacy role/pay changes can improve retention and service levels over time (operational quality catalyst).
Near-term guidance risk: Street commentary (e.g., Oppenheimer) flags potential for management to guide FY26 below consensus when targets are introduced mid-February, which could hit the stock short-term.
Positioning/flow: Insiders are selling (selling amount +136.26% over the last month), which is a near-term sentiment negative.
Political/influential activity: Congress trading in last 90 days shows 1 sale and 0 buys (cautious signal).
Cost pressure risk: pharmacy pay raises/new roles may weigh on near-term expense lines even if strategically positive.
Macro/sector: food disinflation and reduced government benefits could pressure lower-income spend; multiple expansion already substantial per analyst commentary (less room for error).
Latest quarter: 2026/Q3. Growth: Revenue 179.496B (+5.84% YoY) shows steady top-line expansion. Profitability: Net Income 6.143B (+34.21% YoY) and EPS 0.77 (+35.09% YoY) indicate strong operating leverage. Margins: Gross margin 24.95 (+0.16% YoY) modestly improved, supporting the narrative of mix/efficiency gains (automation/e-commerce progress). Overall: fundamentals are strong, but the stock’s near-term trade depends heavily on upcoming earnings/guidance.
Recent trend: Ratings skew strongly positive with multiple price-target raises from late Dec through Jan (many Buy/Outperform/Overweight). Notable raises include Tigress to $135 (Buy), Telsey to $135 (Outperform), Wells Fargo to $130 (Overweight), KeyBanc to $128 (Overweight), Truist to $127 (Buy), Bernstein to $129 (Outperform), Barclays to $125 (Overweight), Oppenheimer to $125 (Outperform). One notable offset: Deutsche Bank resumed with Hold and $119. Wall Street pros: durable value proposition, share gains across income levels, AI/automation efficiencies, improving e-commerce economics, defensive qualities in mixed consumer tape. Wall Street cons: near-term setup could be tricky around FY26 guidance; sector headwinds (food disinflation/benefits), and after significant multiple expansion the stock may be less forgiving on any guidance softness.
